Glenmark Pharmaceuticals, an Indian pharma company, said that it has secured final approval for Clindamycin Phosphate Foam, 1% from the US Food and Drug Administration (FDA).

Clindamycin Phosphate Foam is the generic version of Evoclin Foam, 1%, of Mylan Pharmaceuticals. Evoclin Foam is indicated for the treatment of acne.

As per IQVIA, Evoclin Foam, 1% had recorded annual sales of nearly $12 million for the 12-month period ending July 2021.

Glenmark Pharmaceuticals said that its current portfolio includes 173 products that are authorized for distribution in the US in addition to 47 ANDA’s that are awaiting approval from the FDA.

  Acne, Clindamycin Phosphate Foam, Evoclin Foam, Glenmark Pharmaceuticals, Mylan Pharmaceuticals, US FDA, US Food and Drug Administration, USA